7TH HEIDELBERG MYELOMA WORKSHOP

MULTIPLE MYELOMA – TODAY AND TOMORROW

Congress venue:
Lecture Hall | Heidelberg University Hospital

FRIDAY, APRIL 5TH, 2019
SATURDAY, APRIL 6TH, 2019
DEAR COLLEAGUES,

Welcome to the 7th Heidelberg Myeloma Workshop.

This biennial meeting continues to focus on new developments in multiple myeloma and a panel of internationally renowned experts discuss the range of current therapeutic approaches.

Recent years have seen myeloma patients benefit from more refined diagnostic criteria and a wider range of treatment options. Both the earlier initiation of treatment and a greater appreciation of the importance of targeting sustained deep remissions offer new opportunities to further extend patient survival. Most importantly, there continues to be a growing pipeline of novel agents in phase III trials and immunotherapeutic approaches have shown great promise in myeloma. Finally, the prospect of cure is no longer remote.

Myeloma is, like any cancer, a range of diseases. We are however, now able to make use of clinical, chromosomal and molecular markers to accurately identify robust prognostic groups. For the first time, this is allowing us to deliver increasingly targeted and, ultimately, personalized therapy. In parallel, the use of these novel markers in combination with precise imaging techniques is advancing our understanding of myeloma and our ability to treat it.

We hope that this program will be of interest to you and look forward to welcoming you to Heidelberg.

The language of the meeting is English.

Sincerely,

Prof. Dr. Hartmut Goldschmidt  
Prof. Dr. Marc S. Raab
FRIDAY, APRIL 5TH, 2019

11.00 a.m. – 11.45 a.m.  Registration at the lobby
Coffee, Tea, Drinks, Fingerfoods

11.45 a.m. – 12.00 p.m.
Opening Remarks - 7th Heidelberg Myeloma Workshop
Hartmut Goldschmidt, Heidelberg
Marc S. Raab, Heidelberg
Carsten Müller-Tidow, Heidelberg
Stefan Fröhling, Heidelberg
Michael Baumann, Heidelberg

SESSION I  12.00 p.m. – 1.20 p.m.
Diagnostics and Prognostic Factors
Moderator: Siegfried Janz, Milwaukee

12.00 p.m. – 12.20 p.m.
Major Prognostic Factors in Patients with SMM and MM
Herve Avet-Loiseau, Toulouse

KEY NOTE LECTURE  12.20 p.m. – 12.50 p.m.
Introducing Sagar Lonial (Niels Weinhold)
The Road to Cure in Multiple Myeloma
Sagar Lonial, Atlanta

12.50 p.m. – 1.10 p.m.
Current and Future Concepts in PET - Imaging
Martin Kortüm, Würzburg

1.10 p.m. - 1.30 p.m.
Biology of High-Risk Myeloma „del17p Myeloma: Biology and Prognosis“
Anjan Thakurta, Summit

KEY NOTE LECTURE  1.30 p.m. – 2.00 p.m.
Introducing Shaji Kumar (Marc S. Raab)
How to Define and when to Treat Smoldering MM
Shaji Kumar, Rochester

2.00 p.m. – 2.30 p.m.  Coffee Break

SESSION II  2.30 p.m. – 3.30 p.m.
Role of Immunotherapy in Multiple Myeloma
Moderator: Michael Schmitt, Heidelberg

2.30 p.m. – 2.50 p.m.
Myeloma Biology: Basic Principles of Immunotherapy
Paola Neri, Calgary
2.50 p.m. – 3.10 p.m.
Antibodies in Myeloma: Clinical Efficacy and Management
Niels van de Donk, Amsterdam

3.10 p.m. – 3.30 p.m.
Innovative Immunotherapies Including Car-T Cells
Adam D. Cohen, Philadelphia

KEY NOTE LECTURE  3.30 p.m. – 4.00 p.m.
Introducing Brian Durie (Hartmut Goldschmidt)
MRD - Negativity for all Patients
Brian Durie, Los Angeles

4.00 p.m. – 4.30 p.m.  Coffee Break
Pastries and Fruits

SESSION III   4.30 p.m. – 6.10 p.m.
Current Therapy of Multiple Myeloma
Moderator: Heinz Ludwig, Wien

4.30 p.m. – 4.50 p.m.
First-line Therapy for Non-Transplant Eligible Patients
Christof Scheid, Köln

4.50 p.m. – 5.10 p.m.
Updated Results on Double Transplant in First-line
Michele Cavo, Bologna

5.10 p.m. – 5.30 p.m.
Treatment of High-Risk Myeloma
Marc S. Raab, Heidelberg

5.30 p.m. – 5.50 p.m.
The Role of Allogeneic Transplantation
Nicolaus Kröger, Hamburg-Eppendorf

5.50 p.m. – 6.10 p.m.
When and How to Treat Relapsed Multiple Myeloma
Katja Weisel, Hamburg-Eppendorf

6.10 p.m. – 6.25 p.m.
Summary - Day one
Hartmut Goldschmidt, Heidelberg
SATURDAY, APRIL 6TH, 2019

08.15 - 08.30 a.m.  Hot and cold Beverages

KEY NOTE LECTURE  8.30 a.m. – 9.00 a.m.
Introducing Kenneth Anderson (Marc S. Raab)
The Future of Myeloma Therapy in the Next Decade
Kenneth C. Anderson, Boston

DEBATE  9.00 a.m. – 10.00 a.m.
MRD Driven Therapy - Ready for Primetime
Moderator: Michael Hundemer, Heidelberg

9.00 a.m. – 9.20 a.m.
Techniques for Detection of MRD – Feasibility and Aim for International Consent
Stefanie Huhn, Heidelberg

9.20 a.m. – 9.40 a.m.
YES: MRD Negativity is a Strong Predictor of Clinical Outcomes
Nikhil Munshi, Boston

9.40 a.m. – 10.00 a.m.
NO: Lack of Standardization Suggests it is not yet a Standard of Care in Clinical Practice
Martin Kaiser, London

10.00 a.m. – 10.30 a.m.  Coffee Break

SESSION IV  10.30 a.m. - 11.50 a.m.
Biology and Genomics of Multiple Myeloma
Moderator: Aldo M. Roccaro, Brescia

10.30 a.m. – 10.50 a.m.
Radiogenomics
Leo Rasche, Würzburg

10.50 a.m. – 11.10 a.m.
Genetic Heterogeneity and Genomic Evolution
Niels Weinhold, Heidelberg

11.10 a.m. – 11.30 a.m.
Non-Evasive Techniques for Detection
Bruno Paiva, Pamplona

11.30 a.m. – 11.50 a.m.
Analyzing the Single Myeloma Cell
Jens G. Lohr, Boston
11.50 a.m. – 12.10 p.m.
**Novel Imaging Techniques in Multiple Myeloma**
Jens Hillengaß, Buffalo

12.10 p.m. – 1.20 p.m.  Lunch - Buffet

**SESSION V  1.20 p.m. – 3.20 p.m.**
**Novel Therapeutic Concepts**
*Moderator: Christoph Driessen, St. Gallen*

1.20 p.m. – 1.40 p.m.
**Development of Personalized Medicine in MM**
Nicola Giesen, Heidelberg

1.40 p.m. – 2.00 p.m.
**Emerging Drugs and Targets**
Roman Hajek, Ostrava

2.00 p.m. – 2.20 p.m.
**ProTACs - Targeting the Undrugables?**
Nizar Bahlis, Calgary

2.20 p.m. – 2.40 p.m.
**AL Amyloidosis – Organ Responses to Novel Therapies**
Stefan Schönland, Heidelberg

2.40 p.m. – 3.00 p.m.
**Deutsche Studiengruppe Multiples Myelom**
**Current and Novel Trials of DSMM**
Stefan Knop, Würzburg

3.00 p.m. – 3.20 p.m.
**German-speaking Myeloma Multicenter Group**
**Current and Novel Trials of GMMG**
Hartmut Goldschmidt, Heidelberg

3.20 p.m. – 3.35 p.m.
**Summary of the 7th Heidelberg Myeloma Workshop**
Hartmut Goldschmidt, Heidelberg
SPEAKERS AND CHAIRMEN

Prof. Dr. med. Kenneth C. Anderson, Boston, USA
Prof. Dr. med. Herve Avet-Loiseau, Toulouse, France
Prof. Dr. med. Nizar Bahlis, Calgary, Canada
Prof. Dr. med. Michele Cavo, Bologna, Italy
Prof. Dr. med. Adam D. Cohen, Philadelphia, USA
Prof. Dr. med. Christoph Driessen, St. Gallen, Switzerland
Prof. Dr. med. Brian Durie, Los Angeles, USA
Dr. med. Nicola Giesen, Heidelberg, Germany
Prof. Dr. med. Roman Hajek, Ostrava, Czechia
Prof. Dr. med. Jens Hillenäss, Buffalo, USA
Dr. sc. hum. Stefanie Huhn, Heidelberg, Germany
PD Dr. med. Michael Hundemer, Heidelberg, Germany
Prof. Dr. med. Siegfried Janz, Milwaukee, USA
Dr. med. Martin Kaiser, London, United Kingdom
Prof. Dr. med. Stefan Knop, Würzburg, Germany
PD Dr. med. Martin Kortüm, Würzburg, Germany
Prof. Dr. med. Nicolaus Kröger, Eppendorf, Germany
Prof. Dr. med. Shaji Kumar, Rochester, USA
Dr. med. Jens G. Lohr, Boston, USA
Prof. Dr. med. Sagar Lonial, Atlanta, USA
Prof. Dr. med. Heinz Ludwig, Wien, Österreich
Prof. Dr. med. Nikhil Munshi, Boston, USA
Dr. med. Paola Neri, Calgary, Canada
Prof. Dr. med. Bruno Paiva, Pamplona, Spain
Dr. med. Leo Rasche, Würzburg, Germany
Dr. med. Aldo Roccaro, Brescia, Italy
Prof. Dr. med. Christof Scheid, Köln, Germany
Prof. Dr. med. Michael Schmitt, Heidelberg, Germany
Prof. Dr. med. Stefan Schönlund, Heidelberg, Germany
Dr. med. Anjan Thakurta, Summit, USA
Prof. Dr. med. Niels van de Donk, Amsterdam, Netherlands
Dr. rer. nat. Niels Weinhold, Heidelberg, Germany
Prof. Dr. med. Katja Weisel, Eppendorf, Germany
We would like to thank all our sponsors for supporting the 7th Heidelberg Myeloma Workshop:

<table>
<thead>
<tr>
<th>Sponsor</th>
<th>Address</th>
<th>Contribution</th>
</tr>
</thead>
<tbody>
<tr>
<td>AbbVie Deutschland GmbH &amp; Co.KG</td>
<td>65189 Wiesbaden</td>
<td>€50,000</td>
</tr>
<tr>
<td>Amgen GmbH</td>
<td>80992 München</td>
<td>€45,000</td>
</tr>
<tr>
<td>Adaptive Biotechnologies</td>
<td>Seattle 98102 WA</td>
<td>€7,500</td>
</tr>
<tr>
<td>Bristol-Myers Squibb GmbH &amp; Co. KGaA</td>
<td>80636 München</td>
<td>€30,000</td>
</tr>
<tr>
<td>Celgene GmbH</td>
<td>81829 München</td>
<td>€50,000</td>
</tr>
<tr>
<td>Chugai Pharma Europe Ltd.</td>
<td>60528 Frankfurt am Main</td>
<td>€10,000</td>
</tr>
<tr>
<td>Janssen-Cilag GmbH</td>
<td>41470 Neuss</td>
<td>€30,000</td>
</tr>
<tr>
<td>Molecular Partners AG</td>
<td>8952 Zürich - Schlieren</td>
<td>€10,000</td>
</tr>
<tr>
<td>Sanofi-Aventis Deutschland GmbH</td>
<td>10785 Berlin</td>
<td>€20,000</td>
</tr>
<tr>
<td>Sebia GmbH</td>
<td>36041 Fulda</td>
<td>€2,000</td>
</tr>
<tr>
<td>The Binding Site GmbH</td>
<td>68723 Schwetzingen</td>
<td>€2,000</td>
</tr>
<tr>
<td>Takeda Pharma Vertrieb GmbH &amp; Co. KG</td>
<td>10117 Berlin</td>
<td>€25,000</td>
</tr>
</tbody>
</table>

Sponsors will receive the opportunity to advertise their products before and/or after the event.
ORGANISATION AND CONGRESS VENUE

7TH HEIDELBERG MYELOMA WORKSHOP

University Hospital Heidelberg
Department of Medicine V and
National Center for Tumor Diseases (NCT)
Multiple Myeloma Section
Lecture Hall of the Medical Hospital Heidelberg
Im Neuenheimer Feld 410 | 69120 Heidelberg

CONTACT AND REGISTRATION

Annette Hluzek
Phone: +49 6221 56-5427
E-Mail: annette.hluzek@med.uni-heidelberg.de

Register online at: www.myelomaworkshop.de